Response of patients with refractory myasthenia gravis to rituximab: a retrospective study.

@article{Nowak2011ResponseOP,
  title={Response of patients with refractory myasthenia gravis to rituximab: a retrospective study.},
  author={Richard J. Nowak and Daniel B Dicapua and Nazlee Zebardast and Jonathan M. Goldstein},
  journal={Therapeutic advances in neurological disorders},
  year={2011},
  volume={4 5},
  pages={259-66}
}
INTRODUCTION Myasthenia gravis, an autoimmune disorder of neuromuscular transmission, is treated by an array of immunomodulating therapies. A variable response is observed with certain patients being medically refractory. METHODS We report the results of 14 refractory generalized myasthenia gravis patients (6 AChR+; 8 MuSK+) treated with rituximab. RESULTS Sustained clinical improvement was observed in all patients as well as a reduction of conventional immunotherapies. Prednisone dose… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Pilot trial of rituximab in myasthenia gravis. Neurology 70(Suppl

  • M. A301. Thakre, J. Inshasi, M. Marashi
  • J Neurol
  • 2007
Highly Influential
6 Excerpts

future standards in treatment of myasthenia gravis

  • B. Hain, K. Jordan, M. Deschauer, S. Zierz
  • 2006
Highly Influential
5 Excerpts

CD 20depleting therapy in autoimmune diseases : from basic research to the clinic

  • S. Sathasivam
  • J Intern Med
  • 2010

Similar Papers

Loading similar papers…